BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND...
Blog
Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional investments planned to expand the...